Cargando…

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

(68)Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life of (68)Ga (68 min) creates problems with manufacture and delivery. (18)F (half-life, 110 min) labeling would result in a more practical large-scale p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giesel, Frederik L., Adeberg, Sebastian, Syed, Mustafa, Lindner, Thomas, Jiménez-Franco, Luis David, Mavriopoulou, Eleni, Staudinger, Fabian, Tonndorf-Martini, Eric, Regnery, Sebastian, Rieken, Stefan, El Shafie, Rami, Röhrich, Manuel, Flechsig, Paul, Kluge, Andreas, Altmann, Annette, Debus, Jürgen, Haberkorn, Uwe, Kratochwil, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2021
Materias:	Theranostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679591/ https://www.ncbi.nlm.nih.gov/pubmed/32591493 http://dx.doi.org/10.2967/jnumed.120.245084

Ejemplares similares

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
por: Loktev, Anastasia, et al.
Publicado: (2019)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Physiological FAP-activation in a postpartum woman observed in oncological FAPI-PET/CT
por: Dendl, Katharina, et al.
Publicado: (2021)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers
por: Syed, M., et al.
Publicado: (2020)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74
por: Glatting, Frederik M., et al.
Publicado: (2022)

(68)Ga-FAPI-PET/CT in patients with various gynecological malignancies
por: Dendl, Katharina, et al.
Publicado: (2021)

(68)Ga- or (18)F-FAPI PET/CT—what it can and cannot
por: Mori, Yuriko, et al.
Publicado: (2023)

Monosodium Glutamate Reduces (68)Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
por: Rousseau, Etienne, et al.
Publicado: (2018)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
por: Wickstroem, Katrine, et al.
Publicado: (2019)

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019)

Bone Marrow Absorbed Doses and Correlations with Hematologic Response During (177)Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
por: Hagmarker, Linn, et al.
Publicado: (2019)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
por: Schilham, Melline G.M., et al.
Publicado: (2021)

Preclinical Characterization of the Radioimmunoconjugate (111)In or (90)Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
por: Funase, Yuichi, et al.
Publicado: (2021)

Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT
por: Koerber, Stefan A., et al.
Publicado: (2021)

One-pot and one-step automated radio-synthesis of [(18)F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment
por: Naka, Sadahiro, et al.
Publicado: (2021)

Distinguishing Benign and Malignant Findings on [(68) Ga]-FAPI PET/CT Based on Quantitative SUV Measurements
por: Dabir, M., et al.
Publicado: (2022)

Preclinical evaluation and pilot clinical study of [(18)F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts
por: Hu, Kongzhen, et al.
Publicado: (2022)

FAPI-04 PET/CT Using [(18)F]AlF Labeling Strategy: Automatic Synthesis, Quality Control, and In Vivo Assessment in Patient
por: Jiang, Xiao, et al.
Publicado: (2021)

Visualization of Activated Fibroblasts in Heart Failure with Preserved Ejection Fraction with [(18)F]AlF-NOTA-FAPI-04 PET/CT Imaging
por: Sun, Fangfang, et al.
Publicado: (2023)

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer
por: Ristau, J., et al.
Publicado: (2020)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [(18)F]FAPI-74 with [(18)F]FDG in Patients with PDAC: A Prospective Exploratory Study
por: Novruzov, Emil, et al.
Publicado: (2023)

(18)F-labeled tracers targeting fibroblast activation protein
por: Lindner, Thomas, et al.
Publicado: (2021)

Head-to-head Intra-individual Comparison of [(68)Ga]-FAPI and [(18)F]-FDG PET/CT in Patients with Bladder Cancer
por: Novruzov, E., et al.
Publicado: (2022)

Fibroblast activation protein targeted therapy using [(177)Lu]FAPI-46 compared with [(225)Ac]FAPI-46 in a pancreatic cancer model
por: Liu, Yuwei, et al.
Publicado: (2021)

[(18)F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer
por: Wei, Yuchun, et al.
Publicado: (2021)

Activated fibroblasts in muscle sarcoidosis revealed by [(18)F]FAPI-74 PET
por: Watabe, Tadashi, et al.
Publicado: (2023)

Impact of (18)F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy
por: Debus, Charlotte, et al.
Publicado: (2018)

Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer
por: Liermann, Jakob, et al.
Publicado: (2021)

[(18)F] AlF‑NOTA‑FAPI‑04 PET/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with (18)F-FDG
por: Yang, Liping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d3khpbub7rvr1n3bc2afa16a9n